Clinical Trial Update: Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

Phase II study evaluating the combination of Irinotecan, POF (POFI), and tislelizumab in advanced gastric cancer is being investigated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Irinotecan (Irinotecan)
• POF (POFI)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Gastric Cancer | Phase 2 | Status: UNKNOWN